Diagnocure Inc (DGCRF) 0.0040 $DGCRF DiagnoCure

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Diagnocure Inc (DGCRF) 0.0040 $DGCRF

DiagnoCure announces results of its Annual and Special Meeting of shareholders
PR Newswire - Thu May 19, 4:02PM CDT
DiagnoCure Inc. (TSX: CUR) (OTC Pink: DGCRF) (the "Corporation" today announced that its shareholders have approved all resolutions presented to them in the Management Proxy Circular dated April 14, 2016 and put forth for vote during the annual and special meeting of the shareholders (the "Meeting" held today in Montreal.
CUR.TO: 0.02 (+0.01)

IIROC Trade Resumption - DiagnoCure Inc.
Newsfile Corp - Fri Apr 15, 11:42AM CDT
full story)

Diagnocure announces its decision to proceed with the voluntary Liquidation and Dissolution of the Corporation
CNW Group - Fri Apr 15, 11:25AM CDT
DiagnoCure Inc. (TSX: CUR) ("DiagnoCure" or the "Corporation" announced today that its board of directors (the "Board" has decided, subject to shareholders approval, to proceed with the voluntary liquidation and dissolution of the Corporation (the "Liquidation" in accordance with the provisions of the Québec's Business Corporation's Act (QBCA), and at a time to be determined by the Board in accordance with a liquidation plan (the "Liquidation Plan" . The Board believes this Liquidation will provide shareholders the best alternative to maximize the value of the remaining assets of the Corporation.
CUR.TO: 0.02 (+0.01)

IIROC Trade Halt - DiagnoCure Inc.
Newsfile Corp - Fri Apr 15, 11:23AM CDT
The following issues have been halted by IIROC:

DiagnoCure reports recommendations from two independent proxy advisory firms favorable to the PCA3 asset sale and to the reduction of the stated capital
CNW Group - Tue Feb 02, 6:15AM CST
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) ("DiagnoCure" or the "Corporation" is pleased to announce that the proxy advisory firms Institutional Shareholder Services ("ISS" and Glass Lewis & Co. ("Glass Lewis" have both recommended that DiagnoCure shareholders vote FOR the PCA3 asset sale resolution and FOR the reduction of stated capital resolution. Both resolutions are to be considered at the upcoming special meeting of shareholders to be held on February 12, 2016 at 10:00 a.m., Eastern Time, at the offices of McCarthy Tétrault, 1000 de la Gauchetière Street West, Suite 2500, Montréal (Quebec) H3B 0A2.
CUR.TO: 0.02 (+0.01)

DiagnoCure announces fourth quarter 2015 and year-end results as well as proxy circular filing and business initiatives following the execution of an asset purchase agreement to sell all its assets relating to PCA3
PR Newswire - Thu Jan 21, 4:05PM CST
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) ("DiagnoCure" or the "Corporation" today reported financial and operational results for the fourth quarter 2015 and fiscal year ended October 31, 2015. The Corporation announced a net loss of $2,425,901 or $0.05 per share for the fourth quarter ended October 31, 2015, compared to $461,710 or $0.01 per share for the same period in 2014 and a net loss of $3,600,168 or $0.08 per share for fiscal year 2015 compared to $2,032,151 or $0.05 per share for the same period in 2014. Without taking into account the impairment charges of $2,226,672, the net loss for the fourth quarter and fiscal year ended October 31, 2015 would have been respectively $199,229 and $1,373,496. At the end of the quarter, cash and short-term investments stood at $1,108,937 compared to $2,227,326 at the end of fiscal year 2014.
CUR.TO: 0.02 (+0.01)

World Cancer Diagnostic Testing Markets Report 2016
M2 - Wed Jan 20, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/xg6l8p/cancer_diagnostic) has announced the addition of the "Cancer Diagnostic Testing World Markets" report to their offering. Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Tumor Markers Market Segment Analysis: Size, Growth and Share 4. Diagnostic Methods for Cancer Detection 5. Implications of Molecular Biology for New Diagnostic Cancer Tests 6. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms 7. Business Trends in the Industry 8. Tumor Marker Testing: Important Issues 9. Important New Technology Areas 10. New Cancer Markers in Basic Research 11. Market Trends and Forecasts Companies Mentioned - Partial List - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Ambrilia Biopharma, Inc. - AMDL, Inc. - Asuragen, Inc. - Aureon Laboratories, Inc. - Bard Diagnostics, Inc. - Beckman, Dickinson and Company (BD) Diagnostics - TriPath - Beckman Coulter, Inc. - Biocode S.A. - BioCurex - Biomedical Diagnostics - Biomerica - bioMerieux - BioModa, Inc. - Bruker Daltonics - Byk Gulden - Cepheid - Clarient, Inc. - Correlogic Systems, Inc. - CytoCore (formerly Molecular Diagnostics, Inc.) - Cytogen Corporation (now EUSA Pharma) - diaDexus, Inc. - DiagnoCure, Inc. - Diagnostic Automation / Cortez Diagnostics, Inc. - DRG International, Inc. - Eisai Co., Ltd. - Enigma Diagnostics Ltd. - Epigenomics AG - Exact Sciences Corporation - Exagen Diagnostics, Inc. - Fujirebio Diagnostics, Inc. - Gene Logic, Inc. - Gen-Probe, Inc. For more information visit http://www.researchandmarkets.com/research/xg...diagnostic
EXAS: 20.43 (-0.37), AFFX: 14.01 (+0.02), CPHD: 36.49 (+0.67)

DiagnoCure announces third quarter 2015 results
PR Newswire - Fri Sep 11, 6:30AM CDT
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation" today reported financial and operational results for the third quarter ended July 31, 2015. The Corporation announced a net loss of $274,005 or $0.01 per share for this quarter. At the end of the quarter, cash and temporary investments stood at $1,231,626. Operating expenses decreased by $250,683, to $406,846 for the third quarter of 2015 from $657,529 for the same period of 2014. The net loss before non-cash elements decreased by 54%, from $406,853 for the third quarter of 2014 to $186,335 for the same period of 2015. These decreases are attributable primarily to the reduction of operating expenses implemented in the first quarter of 2015.
CUR.TO: 0.02 (+0.01)

DiagnoCure announces second quarter 2015 results and restructures its Board of directors
CNW Group - Fri Jun 12, 6:30AM CDT
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation" today reported financial and operational results for the second quarter ended April 30, 2015. The Corporation announced a net loss of $567,991 or $0.01 per share for this quarter. At the end of the quarter, cash and temporary investments stood at $1,574,957. Operating expenses, before restructuring charges of $188,964, decreased by $158,278, to $508,812 for the second quarter of 2015 from $667,090 for the same period of 2014. The net loss before non-cash elements and restructuring charges decreased by a third, from $431,706 for the second quarter of 2014 to $289,228 for the same period of 2015. These decreases are attributable primarily to the reduction of operating expenses implemented in the first quarter of 2015.
CUR.TO: 0.02 (+0.01)

DiagnoCure's new prostate cancer multimarker urine test featured at a recent press event of the American Urological Association
CNW Group - Wed May 20, 4:01PM CDT
DiagnoCure Inc. (TSX: CUR; OTCQX: DGCRF) (the "Corporation" today reports that the results of the prospective trial on its prostate cancer panel (PCP) urine test were well received by the urologist community attending the 2015 Annual Meeting of the American Urological Association (AUA) held from May 15 to May 19 in New Orleans, Louisiana.
CUR.TO: 0.02 (+0.01)

DiagnoCure announces results of its Annual and General Meeting of shareholders
CNW Group - Thu Apr 30, 5:30PM CDT
DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation" today announced that its shareholders have approved all resolutions presented to them in the Management Proxy Circular dated March 5, 2015 and put forth for vote during the shareholders meeting held today in Montreal.
CUR.TO: 0.02 (+0.01)

DiagnoCure provides business up-date
CNW Group - Thu Apr 23, 4:00PM CDT
DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation" today reports on its continuing efforts to improve corporate value for its shareholders and preserving operating funds to ensure all options for the Corporation. These continuing efforts include: (1) maintaining productive discussions regarding the licensing of the Corporation's assets, (2) continuing discussions with a select group of companies regarding a potential strategic combination of assets and, (3) implementation of additional steps under the contingency plan of the Corporation.
CUR.TO: 0.02 (+0.01)

DiagnoCure announces fourth quarter 2014 and year-end results
CNW Group - Fri Jan 23, 6:30AM CST
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation" today reported financial and operational results for the fourth quarter 2014 and fiscal year ended October 31, 2014. The Corporation announced a net loss of $461,710 or $0.01 per share for the fourth quarter ended October 31, 2014, compared to $1,334,099 or $0.03 per share for the same period in 2013 and a net loss of $2,032,151 or $0.05 per share for fiscal year 2014 compared to $3,566,942 or $0.08 per share for the same period in 2013. At the end of the quarter, cash and short-term investments stood at $2,227,326 compared to $4,190,296 at the end of fiscal year 2013.
CUR.TO: 0.02 (+0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 103

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 110

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 39

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 95

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 142

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 10

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 423

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 43

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 52

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 53

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading

Top 5 Most Recently Viewed Articles

STMicroelectronics Unveils Latest Financial Performance Insights

Updated Category News Views 215

Overview of STMicroelectronics’ Third Quarter Results STMicroelectronics N.V. (“ST”) (NYSE: STM), a prominent figure in the semiconductor sector, announced its financial results for the third quarter, showcasing a robust revenue of $3.25 billion. This figure represents a gross margin of 37.8% and an operating margin of 11.7%, culminating in a net income of $351...

Continue Reading
Celebrating the Unique Career Opportunities at McDonald's

Updated Category News Views 654

Explore the Benefits of Working at McDonald's Finding a meaningful job can be tough, but for many, McDonald's is more than just a fast-food place. It's a stepping stone for personal and professional development. Numerous individuals have experienced major career growth thanks to their time at McDonald's, reflecting the company’s dedication to helping its employees...

Continue Reading
Key Insights on New Fortress Energy Class Action & Legal Help

Updated Category News Views 153

Understanding the New Fortress Energy Class Action Investors in New Fortress Energy Inc. (NASDAQ: NFE) should be cognizant of legal developments surrounding their investments. This class action lawsuit emerges from concerns that misrepresentations regarding the company's revenue and growth forecasts misled investors during a designated class period. Important Details...

Continue Reading
Mauna Kea Technologies Reports Promising IBS Findings with Cellvizio

Updated Category News Views 58

Mauna Kea Technologies Presents Clinical Advances for Cellvizio in IBS Mauna Kea Technologies (Euronext Growth: ALMKT), the innovative creator of Cellvizio, recently unveiled new clinical insights regarding its advanced laser endomicroscopy system. This technology showcases potential in diagnosing and managing food intolerances, specifically focusing on individuals...

Continue Reading
Resilience in Asia's Stock Markets Amid Mixed Signals

Updated Category News Views 72

Resilience in Asia's Stock Markets Amid Mixed Signals Most Asian stocks showed little movement on a recent Friday, characterized by uncertainty regarding U.S. interest rates and the approaching presidential election. However, the situation was different for Chinese shares, which turned positive following data that revealed growth in the economy, meeting investor...

Continue Reading